I am a bioinformatician working in the Experimental Cancer Genetics group at the Wellcome Trust Sanger Institute. My primary interest is to identify somatic variations in mammalian cancer genomes and their role in cancer development and progression. I am also interested in developing bioinformatics tools for efficient data processing and interpretation.
Our group combines a number of state of the art technologies (e.g. Next Generation Sequencing and Genome Editing ) to investigate cancer genomes from different perspective, which produces a large volume of sequencing data. Using my expertise in data analysis and software development, I develop bioinformatics tools to analyze this torrent of data and try to draw a meaningful picture of cancer machanism.
I also have a strong interest in machine learning and it's application in cancer research. Large scale genome and epignome profiling studies such as the ENCODE, TCGA have opened new research avenues to fight cancer beyond the realm of protein coding genes. My recent research interest includes prioritization of regulatory (noncoding) mutations in cancer by applying advance machine learning techniques on an integrated genomic and epigenomic data.
Adenoma development in familial adenomatous polyposis and MUTYH-associated polyposis: somatic landscape and driver genes.
The Journal of pathology 2016;238;1;98-108
Inactivating CUX1 mutations promote tumorigenesis.
Nature genetics 2014;46;1;33-8
Cake: a bioinformatics pipeline for the integrated analysis of somatic variants in cancer genomes.
Bioinformatics (Oxford, England) 2013;29;17;2208-10
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.
Proceedings of the National Academy of Sciences of the United States of America 2015;112;6;E536-45
Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis.
Cancer research 2012;72;15;3817-3827